| Literature DB >> 35426357 |
Jamie Lopez Bernal1, Nikolaos Panagiotopoulos2, Chloe Byers1, Tatiana Garcia Vilaplana1, Nicki Boddington1, Xu-Sheng Zhang2, Andre Charlett2, Suzanne Elgohari1, Laura Coughlan1, Rosie Whillock1, Sophie Logan3, Hikaru Bolt3, Mary Sinnathamby1, Louise Letley1, Pauline MacDonald1, Roberto Vivancos3, Obaghe Edeghere3, Charlotte Anderson3, Karthik Paranthaman3, Simon Cottrell4, Jim McMenamin5, Maria Zambon6, Gavin Dabrera6, Mary Ramsay1, Vanessa Saliba1.
Abstract
BackgroundHouseholds appear to be the highest risk setting for COVID-19 transmission. Large household transmission studies in the early stages of the pandemic in Asia reported secondary attack rates ranging from 5 to 30%.AimWe aimed to investigate the transmission dynamics of COVID-19 in household and community settings in the UK.MethodsA prospective case-ascertained study design based on the World Health Organization FFX protocol was undertaken in the UK following the detection of the first case in late January 2020. Household contacts of cases were followed using enhanced surveillance forms to establish whether they developed symptoms of COVID-19, became confirmed cases and their outcomes. We estimated household secondary attack rates (SAR), serial intervals and individual and household basic reproduction numbers. The incubation period was estimated using known point source exposures that resulted in secondary cases.ResultsWe included 233 households with two or more people with 472 contacts. The overall household SAR was 37% (95% CI: 31-43%) with a mean serial interval of 4.67 days, an R0 of 1.85 and a household reproduction number of 2.33. SAR were lower in larger households and highest when the primary case was younger than 18 years. We estimated a mean incubation period of around 4.5 days.ConclusionsRates of COVID-19 household transmission were high in the UK for ages above and under 18 years, emphasising the need for preventative measures in this setting. This study highlights the importance of the FFX protocol in providing early insights on transmission dynamics.Entities:
Keywords: COVID-19; Incubation period; Reproduction number; Secondary Attack Rate; Transmission dynamics; serial interval
Mesh:
Year: 2022 PMID: 35426357 PMCID: PMC9012093 DOI: 10.2807/1560-7917.ES.2022.27.15.2001551
Source DB: PubMed Journal: Euro Surveill ISSN: 1025-496X
FigureFlowchart of COVID-19 case-patients and household contacts, United Kingdom, 2020 (n = 365 primary cases)
Characteristics of COVID-19 households and household contacts, United Kingdom, January to March 2020 (n = 472 contacts)
| Non-casesa | Probable secondary cases | Confirmed SARS-CoV-2 | All | |||||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | |
| Total | 311 | 96 | 65 | 472 | ||||
| Lost to follow-up | ||||||||
| Yes | 24 | 7.7 | 3 | 3.1 | 5 | 7.7 | 32 | 6.8 |
| No | 287 | 92.3 | 93 | 96.9 | 60 | 92.3 | 440 | 93.2 |
| Household size (number of people) | ||||||||
| 2 | 39 | 12.5 | 17 | 17.7 | 21 | 32.3 | 77 | 16.3 |
| 3 | 63 | 20.3 | 25 | 26.0 | 18 | 27.7 | 106 | 22.5 |
| 4 | 104 | 33.4 | 30 | 31.2 | 18 | 27.7 | 152 | 32.2 |
| 5 | 61 | 19.6 | 18 | 18.8 | 7 | 10.8 | 86 | 18.2 |
| 6 | 22 | 7.1 | 4 | 4.2 | 1 | 1.5 | 27 | 5.7 |
| 7 | 22 | 7.1 | 2 | 2.1 | 0 | 0.0 | 24 | 5.1 |
| Age (years) | ||||||||
| <18 | 126 | 40.5 | 33 | 34.4 | 9 | 13.8 | 168 | 35.6 |
| 18–64 | 173 | 55.6 | 63 | 65.6 | 50 | 76.9 | 286 | 60.6 |
| ≥ 65 | 12 | 3.9 | 0 | 0.0 | 6 | 9.2 | 18 | 3.8 |
| Sex | ||||||||
| Female | 161 | 51.8 | 46 | 47.9 | 34 | 52.3 | 241 | 51.1 |
| Male | 150 | 48.2 | 50 | 52.1 | 31 | 47.7 | 231 | 48.9 |
| Comorbidities | ||||||||
| Any comorbidityb | 30 | 9.6 | 13 | 13.5 | 17 | 26.2 | 60 | 12.7 |
| Asthma requiring medication | 13 | 4.2 | 2 | 2.1 | 10 | 15.4 | 25 | 5.3 |
| Respiratory disease excluding asthma | 5 | 1.6 | 3 | 3.1 | 2 | 3.1 | 10 | 2.1 |
| Diabetes | 4 | 1.3 | 2 | 2.1 | 1 | 1.5 | 7 | 1.5 |
| Heart disease | 5 | 1.6 | 1 | 1.0 | 1 | 1.5 | 7 | 1.5 |
| Immunodeficiency | 4 | 1.3 | 1 | 1.0 | 1 | 1.5 | 6 | 1.3 |
| Malignancy | 0 | 0.0 | 3 | 3.1 | 2 | 3.1 | 5 | 1.1 |
| Neurological disease | 2 | 0.6 | 1 | 1.0 | 2 | 3.1 | 5 | 1.1 |
| Kidney disease | 2 | 0.6 | 1 | 1.0 | 1 | 1.5 | 4 | 0.8 |
| No comorbidity | 252 | 81.0 | 80 | 83.3 | 45 | 69.2 | 377 | 79.9 |
| Unknown | 29 | 9.3 | 3 | 3.1 | 3 | 4.6 | 35 | 7.4 |
COVID-19: coronavirus disease.
a Non-cases include household contacts with no respiratory symptoms, contacts who developed respiratory symptoms > 14 days after symptom onset in the primary case, and contacts with unrelated prior illnesses (identified through review of household symptomology dates and HPZone case notes).
b Seven household contacts had multimorbidity, therefore the total of the number of contacts with each individual comorbidity will sum to more than the total number of contacts with ‘Any comorbidity’.
Unadjusted symptomatic secondary attack rates and odds ratios for secondary SARS-CoV-2 infection (probable and confirmed secondary cases), United Kingdom, January to March 2020 (n =440)
| Variable levels | SAR | 95% CI | OR | 95% CI | |
|---|---|---|---|---|---|
| Household | |||||
| Household size | 2 | 0.49 | 0.37–0.60 | 1.00 | Reference value |
| 3 | 0.41 | 0.30–0.51 | 0.62 | 0.26–1.53 | |
| 4 | 0.32 | 0.22–0.42 | 0.36 | 0.15–0.90 | |
| ≥ 5 | 0.25 | 0.13–0.37 | 0.23 | 0.07–0.71 | |
| Interactions | |||||
| Sex | Male → Male | 0.37 | 0.26–0.48 | 1.00 | Reference value |
| Male → Female | 0.42 | 0.33–0.50 | 1.36 | 0.69–2.69 | |
| Female → Male | 0.34 | 0.26–0.43 | 0.85 | 0.34–2.13 | |
| Female → Female | 0.29 | 0.16–0.42 | 0.59 | 0.19–1.84 | |
| Comorbidities | None → none | 0.37 | 0.29–0.45 | 1.00 | |
| None → comorbidities | 0.46 | 0.30–0.62 | 1.70 | 0.58–4.95 | |
| Comorbidities → none | 0.36 | 0.25–0.47 | 0.95 | 0.39–2.29 | |
| Comorbidities → comorbidities | 0.46 | 0.28–0.64 | 1.71 | 0.53–5.56 | |
| Characteristics of contact | |||||
| Sex | Male | 0.36 | 0.29–0.43 | 1.00 | Reference value |
| Female | 0.38 | 0.31–0.45 | 1.15 | 0.68–1.94 | |
| Age group (years) | < 18 | 0.30 | 0.21–0.39 | 0.62 | 0.28–1.38 |
| 18–34 | 0.37 | 0.28–0.47 | 1.00 | Reference value | |
| 35–64 | 0.43 | 0.35–0.51 | 1.38 | 0.67–2.85 | |
| ≥ 65 | 0.35 | 0.13–0.57 | 0.86 | 0.19–3.87 | |
| Characteristics of primary case | |||||
| Sex | Male | 0.41 | 0.33–0.49 | 1.00 | Reference value |
| Female | 0.33 | 0.25–0.41 | 0.61 | 0.30–1.26 | |
| Age group (years) | < 18 | 0.89 | 0.7–1.05 | 41.89 | 4.46–393.02 |
| 18–64 | 0.35 | 0.29–0.41 | 1.00 | ||
| ≥ 65 | 0.42 | 0.25–0.59 | 1.51 | 0.53–4.26 | |
| Hospital admission | Without hospital admission | 0.43 | 0.36–0.51 | 1.00 | Reference value |
| With hospital admission | 0.28 | 0.20–0.36 | 0.37 | 0.18–0.77 | |
| Cough sneezing | Without cough/sneeze | 0.32 | 0.19–0.46 | 1.00 | |
| With cough/sneeze | 0.38 | 0.32–0.44 | 1.42 | 0.54–3.70 | |
| Overall | 0.37 | 0.31–0.43 | NA | ||
CI: confidence interval; NA: not applicable; OR: odds ratio; SAR: secondary attack rate; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
Adjusted symptomatic secondary attack rates and odds ratios for secondary SARS-CoV-2 infection (probable and confirmed secondary cases), United Kingdom, January to March 2020 (n =440)
| Variable | Levels | SAR | 95% CI | Adjusted OR | 95% CI |
|---|---|---|---|---|---|
| Household | |||||
| Household size | 2 | 0.48 | 0.36–0.60 | 1.00 | Reference value |
| 3 | 0.40 | 0.29–0.52 | 0.67 | 0.28–1.60 | |
| 4 | 0.33 | 0.23–0.44 | 0.46 | 0.19–1.10 | |
| ≥ 5 | 0.22 | 0.11–0.33 | 0.22 | 0.076–0.66 | |
| Characteristics of contact | |||||
| Sex | Male | 0.36 | 0.28–0.43 | 1.00 | Reference value |
| Female | 0.32 | 0.24–0.39 | 0.80 | 0.46–1.40 | |
| Age group (years) | < 18 | 0.29 | 0.19–0.39 | 0.73 | 0.32–1.60 |
| 18–34 | 0.34 | 0.24–0.44 | 1.00 | Reference value | |
| 35–64 | 0.39 | 0.31–0.47 | 1.30 | 0.65–2.70 | |
| ≥ 65 | 0.26 | 0.03–0.50 | 0.62 | 0.12–3.30 | |
| Characteristics of primary case | |||||
| Sex | Male | 0.38 | 0.29–0.46 | 1.00 | Reference value |
| Female | 0.29 | 0.21–0.37 | 0.60 | 0.30–1.20 | |
| Age group (years) | < 18 | 0.92 | 0.80–1.00 | 61 | 7–527 |
| 18–64 | 0.31 | 0.25–0.37 | 1.00 | Reference value | |
| ≥ 65 | 0.38 | 0.17–0.58 | 1.40 | 0.44–4.70 | |
| Hospital admission | Without hospital admission | 0.40 | 0.32–0.48 | 1.00 | Reference value |
| With hospital admission | 0.25 | 0.17–0.33 | 0.40 | 0.20–0.80 | |
| Cough/sneeze | No cough/sneeze | 0.29 | 0.18–0.41 | 1.00 | Reference value |
| Cough/sneeze | 0.34 | 0.28–0.41 | 1.40 | 0.61–3.00 | |
CI: confidence interval; OR: odds ratio; SAR: secondary attack rate; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
Adjusted serial intervals using marginal means and hazard ratios, SARS-CoV-2 infection, United Kingdom, January to March 2020 (n =440)
| Variable | Levels | Serial interval | 95% CI | HR | 95% CI |
|---|---|---|---|---|---|
| Primary case | |||||
| Imported | No | 5.99 | 4.67–7.69 | 1.00 | |
| Yes | 4.75 | 3.57–6.33 | 1.40 | 0.96–2.04 | |
| Cough | No | 6.79 | 4.96–9.30 | 1.00 | |
| Yes | 5.04 | 3.96–6.41 | 1.55 | 1.06–2.26 | |
| Fever | No | 4.50 | 3.48–5.81 | 1.00 | |
| Yes | 5.73 | 4.42–7.43 | 0.70 | 0.50–1.00 | |
| Age group (years) | < 18 | 4.04 | 2.73–5.96 | 1.50 | 0.89–2.54 |
| 18–64 | 5.34 | 4.22–6.75 | 1.00 | ||
| ≥ 65 | 6.59 | 3.82–11.38 | 0.73 | 0.35–1.54 | |
| Sex | Male | 5.00 | 3.93–6.37 | 1.00 | |
| Female | 5.82 | 4.30–7.89 | 0.80 | 0.54–1.18 | |
| Contact | |||||
| Age group (years) | < 18 | 5.14 | 4.33–6.10 | 1.06 | 0.70–1.59 |
| 18–34 | 5.34 | 4.22–6.75 | 1.00 | ||
| 35–64 | 4.48 | 3.60–5.58 | 1.29 | 0.87–1.91 | |
| ≥ 65 | 5.63 | 2.53–12.5 | 0.93 | 0.29–2.96 | |
CI: confidence interval; HR: hazard ratio; SAR: secondary attack rate; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
Summary of incubation period and timing of exposure in relation to primary COVID-19 case symptom onset for contacts with a point source exposure, United Kingdom, January to March 2020 (n = 286)
| Incubation period (days) | Timing of exposure after symptom onset of primary case (days) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Status of contact | Number of contacts included | Mean | SD | Median | IQR | Range | Mean | SD | Median | IQR | Range |
| Probable and confirmed secondary cases | 45a | 4.51 | 2.66 | 4.00 | 2.00–7.00 | 0.00–11.00 | 2.37 | 3.36 | 1.00 | 0.00–4.00 | 0.00–14.00 |
| Confirmed secondary cases | 12 | 4.75 | 2.34 | 4.00 | 3.75–5.00 | 2.00–11.00 | 1.33 | 1.61 | 1.00 | 0.00–1.25 | 0.00–5.00 |
| Did not develop symptoms | 241 | NA | NA | NA | 2.71 | 2.74 | 2.00 | 0.00–5.00 | 0.00–9.00 | ||
COVID-19: coronavirus disease; IQR: interquartile range; NA: not applicable; SD: standard deviation.
a Four persons were excluded from timing of exposure analysis because no onset date was available for the primary case.